Our Partnership with OpenEvidence: The Intelligence Layer for Modern Medicine

We’re thrilled to announce our investment in OpenEvidence, the AI-powered medical search platform that’s a total game-changer for the healthcare industry. Designed from the ground up for medical professionals, OpenEvidence organizes the world’s medical knowledge to make it more useful, open, accessible, and understandable.

Since launching in 2023, OpenEvidence has seen explosive adoption across the medical community, becoming the most widely used medical search engine in the U.S. Today, more than half of all U.S. physicians log in daily to make high-stakes clinical decisions. When we first heard about OpenEvidence, we asked physicians what they thought. The response was overwhelming, and it’s rare to see this level of enthusiasm for new technology in medicine:

“It’s the best medical app I’ve ever used in my 30 year career; my team and I use it daily.”

“For this upcoming generation of doctors, this is a never-go-back moment.”

“OpenEvidence lets me think through a case with a broader differential and prompts consideration of the ‘can’t miss’ diagnoses. It’s become core to my day to day.”

The problem OpenEvidence is solving is universal: the medical field is drowning in information. The body of medical research doubles every few months, an impossible volume for any clinician to keep up with. OpenEvidence solves this problem, bringing real-time, peer-reviewed insights directly to clinicians at the point of care.

In an industry where trust is everything, physicians need answers grounded in science and delivered with speed and context. Unlike general-purpose large language models, OpenEvidence is purpose-built for medicine and trained exclusively on high-quality, peer-reviewed sources. Its partnerships with The New England Journal of Medicine and JAMA provide a foundation of credibility that sets a new standard for accuracy in clinical AI. OpenEvidence has collected data on more than 100 million clinical consultations, and earlier this year became the first AI platform in history to score 100% on the US Medical Licensing Exam. The company now powers more than 15 million clinical consultations every month. To put that in perspective, in 2025, roughly one in three Americans will be treated by a doctor using OpenEvidence.

Behind this momentum are co-founders Daniel Nadler (CEO)and Zach Ziegler (CTO), and a world-class team of PhD researchers, engineers, doctors, and operators. As a two-time founder, Daniel has spent his career building tools that make complex information accessible and actionable. Before OpenEvidence, he founded Kensho, the pioneering AI analytics platform acquired by S&P Global.

With a stellar reputation in the medical community, it’s no surprise that OpenEvidence is attracting exceptional technical talent and experienced healthcare veterans. The team has completely reimagined how technology is delivered to healthcare providers and aligned the business directly with the interests of clinicians, building loyalty from the ground up.

We couldn’t be more excited about the mission and to be partnering with Daniel, Zach, and the entire OpenEvidence team as they build the intelligence layer for modern medicine.